Trials / Completed
CompletedNCT06501534
A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
A Randomized, Open Label, Multicenter, Parallel-group, Positive-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid. This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Febuxostat | Tablets, Once a day (QD), Per oral |
| DRUG | IBI128 | Other Names: LC350189, Tigulixostat,Tablets, Once a day (QD), Per oral |
Timeline
- Start date
- 2024-07-10
- Primary completion
- 2024-12-13
- Completion
- 2025-01-09
- First posted
- 2024-07-15
- Last updated
- 2025-03-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06501534. Inclusion in this directory is not an endorsement.